Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385514156> ?p ?o ?g. }
- W4385514156 abstract "Importance The combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, due to rapid publication of new studies that attained their predefined primary end points, a lack of robust cross-trial comparison of first-line therapies, and diverging clinical guidelines, no clear-cut treatment flowchart and sequence of therapies are available. This critical analysis of the recommendations for the management of advanced HCC from the main scientific societies in the US and Europe adopted an integrated approach to provide information on the clinical benefit (overall survival and progression-free survival) and safety profile of these therapies using the European Society for Medical Oncology (ESMO)–Magnitude of Clinical Benefit Scale (MCBS) score and an ad hoc network meta-analysis. Observations There is a major consensus among guidelines that atezolizumab plus bevacizumab has a primacy as the recommended first-line treatment of choice in advanced HCC. On progression after immunotherapy-containing regimens and for patients with contraindications for immunotherapies, most guidelines maintain the established treatment hierarchy, recommending lenvatinib or sorafenib as the preferred options, followed by either regorafenib, cabozantinib, or ramucirumab. Thus far, the first-line immune-based regimen of tremelimumab plus durvulumab has been integrated only in the American Association for the Study of Liver Diseases guidance document and the latest National Comprehensive Cancer Network guidelines and is recommended for patients with a high risk of gastrointestinal bleeding. Overall, in the first-line setting, both atezolizumab plus bevacizumab and sintilimab plus IBI305 (a bevacizumab biosimilar) received the highest ESMO-MCBS score of 5, indicating a substantial magnitude of clinical benefit. In a network meta-analysis, no significant differences in overall survival were found among the various combination regimens. However, the newly reported combination of camrelizumab plus rivoceranib was associated with a significantly higher risk of treatment-related adverse events compared with atezolizumab plus bevacizumab (relative risk, 1.59; 95% CI, 1.25-2.03; P &lt; .001). Conclusions and Relevance This narrative review found that atezolizumab plus bevacizumab is regarded as the primary standard of care for advanced HCC in the first-line setting. These findings from integrating the recommendations from scientific societies’ guidelines for managing advanced HCC along with new data from cross-trial comparisons may aid clinicians in decision-making and guide them through a rapidly evolving and complex treatment landscape." @default.
- W4385514156 created "2023-08-04" @default.
- W4385514156 creator A5051804509 @default.
- W4385514156 creator A5052975894 @default.
- W4385514156 creator A5073989429 @default.
- W4385514156 creator A5076456783 @default.
- W4385514156 creator A5088674436 @default.
- W4385514156 date "2023-08-03" @default.
- W4385514156 modified "2023-09-27" @default.
- W4385514156 title "Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma" @default.
- W4385514156 cites W1660053632 @default.
- W4385514156 cites W1828082159 @default.
- W4385514156 cites W1964051982 @default.
- W4385514156 cites W1971837077 @default.
- W4385514156 cites W1986215651 @default.
- W4385514156 cites W2502891277 @default.
- W4385514156 cites W2560499218 @default.
- W4385514156 cites W2753603515 @default.
- W4385514156 cites W2761635936 @default.
- W4385514156 cites W2787358630 @default.
- W4385514156 cites W2805592007 @default.
- W4385514156 cites W2809889937 @default.
- W4385514156 cites W2908573150 @default.
- W4385514156 cites W2968669882 @default.
- W4385514156 cites W2990602950 @default.
- W4385514156 cites W2998269674 @default.
- W4385514156 cites W3025022288 @default.
- W4385514156 cites W3033218405 @default.
- W4385514156 cites W3044786201 @default.
- W4385514156 cites W3090413519 @default.
- W4385514156 cites W3094496272 @default.
- W4385514156 cites W3100629716 @default.
- W4385514156 cites W3128927131 @default.
- W4385514156 cites W3133992342 @default.
- W4385514156 cites W3165752903 @default.
- W4385514156 cites W3166753505 @default.
- W4385514156 cites W3169705253 @default.
- W4385514156 cites W3173947248 @default.
- W4385514156 cites W3180754516 @default.
- W4385514156 cites W3207557929 @default.
- W4385514156 cites W3212903603 @default.
- W4385514156 cites W4200158019 @default.
- W4385514156 cites W4200388794 @default.
- W4385514156 cites W4205155919 @default.
- W4385514156 cites W4205890422 @default.
- W4385514156 cites W4210774372 @default.
- W4385514156 cites W4212895371 @default.
- W4385514156 cites W4220787479 @default.
- W4385514156 cites W4223425949 @default.
- W4385514156 cites W4224986642 @default.
- W4385514156 cites W4225146220 @default.
- W4385514156 cites W4226409953 @default.
- W4385514156 cites W4245784696 @default.
- W4385514156 cites W4281645619 @default.
- W4385514156 cites W4283325186 @default.
- W4385514156 cites W4283812631 @default.
- W4385514156 cites W4295677793 @default.
- W4385514156 cites W4295837456 @default.
- W4385514156 cites W4297986221 @default.
- W4385514156 cites W4297986244 @default.
- W4385514156 cites W4300690634 @default.
- W4385514156 cites W4318245406 @default.
- W4385514156 cites W4377011124 @default.
- W4385514156 doi "https://doi.org/10.1001/jamaoncol.2023.2677" @default.
- W4385514156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37535375" @default.
- W4385514156 hasPublicationYear "2023" @default.
- W4385514156 type Work @default.
- W4385514156 citedByCount "0" @default.
- W4385514156 crossrefType "journal-article" @default.
- W4385514156 hasAuthorship W4385514156A5051804509 @default.
- W4385514156 hasAuthorship W4385514156A5052975894 @default.
- W4385514156 hasAuthorship W4385514156A5073989429 @default.
- W4385514156 hasAuthorship W4385514156A5076456783 @default.
- W4385514156 hasAuthorship W4385514156A5088674436 @default.
- W4385514156 hasConcept C121608353 @default.
- W4385514156 hasConcept C126322002 @default.
- W4385514156 hasConcept C143998085 @default.
- W4385514156 hasConcept C177713679 @default.
- W4385514156 hasConcept C2775949291 @default.
- W4385514156 hasConcept C2776248978 @default.
- W4385514156 hasConcept C2776264508 @default.
- W4385514156 hasConcept C2776694085 @default.
- W4385514156 hasConcept C2777701055 @default.
- W4385514156 hasConcept C2777802072 @default.
- W4385514156 hasConcept C2778019345 @default.
- W4385514156 hasConcept C2778695046 @default.
- W4385514156 hasConcept C2779551604 @default.
- W4385514156 hasConcept C2780030458 @default.
- W4385514156 hasConcept C2781064419 @default.
- W4385514156 hasConcept C526805850 @default.
- W4385514156 hasConcept C535046627 @default.
- W4385514156 hasConcept C71924100 @default.
- W4385514156 hasConceptScore W4385514156C121608353 @default.
- W4385514156 hasConceptScore W4385514156C126322002 @default.
- W4385514156 hasConceptScore W4385514156C143998085 @default.
- W4385514156 hasConceptScore W4385514156C177713679 @default.
- W4385514156 hasConceptScore W4385514156C2775949291 @default.
- W4385514156 hasConceptScore W4385514156C2776248978 @default.
- W4385514156 hasConceptScore W4385514156C2776264508 @default.
- W4385514156 hasConceptScore W4385514156C2776694085 @default.